Sanofi Defends Dupixent Patents, but Execs Insist It Has Nothing to Do with CEO Change

Why It Matters

Dupixent’s continued patent coverage safeguards Sanofi’s cash flow while the leadership change could unsettle investors if not clearly separated from product strategy. The evolving Regeneron partnership and pipeline progress will shape the company’s post‑Dupixent growth trajectory.

Key Takeaways

• Dupixent generated $4.9 billion in Q1, up 31%.
• Patents protect Dupixent until 2045 despite upcoming LOE.
• CEO change unrelated to patent strategy, interim CEO reassures investors.
• Regeneron’s cost share drops to zero by 2027, affecting partnership.
• New pipeline products added $1.4 billion, lifting revenue to $13.9 billion.

Pulse Analysis

Dupixent remains Sanofi’s cash‑cow, and the company’s decision to publicly outline a "web of patents" through 2045 signals a proactive defense against generic competition. By emphasizing the breadth of its intellectual property, Sanofi aims to reassure a nervous investor base that revenue streams will stay intact even as the biologic approaches its loss‑of‑exclusivity window. This approach mirrors broader industry trends where firms leverage extended patent families and formulation tweaks to delay market entry of biosimilars.

The abrupt CEO transition adds a layer of complexity, but Sanofi’s interim leadership has been careful to decouple the change from its product strategy. While the departure of Paul Hudson could have been interpreted as a reaction to looming patent challenges, executives highlighted that the leadership shift is unrelated to Dupixent’s roadmap. Meanwhile, Regeneron’s diminishing financial contribution—set to reach zero by 2027—will reshape the profit‑sharing dynamics of the partnership, prompting Sanofi to accelerate its own follow‑on programs such as itepekimab, despite recent trial setbacks.

Beyond Dupixent, Sanofi’s broader portfolio showed resilience, with newly launched therapies contributing $1.4 billion and overall revenue climbing to $13.9 billion, outpacing consensus. This growth underscores the company’s successful diversification into oncology, rare diseases, and vaccines, positioning it to offset any future erosion in Dupixent’s earnings. Analysts will watch how the incoming CEO, Belén Garijo, balances continued patent vigilance with accelerating pipeline development to sustain momentum in a competitive biotech landscape.